Edition:
United Kingdom

Tonix Pharmaceuticals Holding Corp (TNXP.OQ)

TNXP.OQ on NASDAQ Stock Exchange Global Market

4.15USD
20 Jul 2018
Change (% chg)

$-0.04 (-0.95%)
Prev Close
$4.19
Open
$4.16
Day's High
$4.21
Day's Low
$4.02
Volume
12,105
Avg. Vol
26,160
52-wk High
$5.10
52-wk Low
$2.72

Chart for

About

Tonix Pharmaceuticals Holding Corp. is a clinical-stage pharmaceutical company. The Company's drug development programs are directed toward disorders affecting the central nervous system (CNS), and include fibromyalgia (FM), and post-traumatic stress disorder (PTSD). It is focused on developing a portfolio of product candidates,... (more)

Overall

Beta: 2.98
Market Cap(Mil.): $36.27
Shares Outstanding(Mil.): 7.51
Dividend: --
Yield (%): --

Financials

  TNXP.OQ Industry Sector
P/E (TTM): -- 85.33 32.76
EPS (TTM): -6.90 -- --
ROI: -77.69 2.22 14.61
ROE: -77.82 3.86 16.34

BRIEF-Tonix Pharmaceuticals Holding Says Files For Mixed Shelf Of Up To $75 Mln

* TONIX PHARMACEUTICALS HOLDING SAYS FILES FOR MIXED SHELF OF UP TO $75 MILLION - SEC FILING Source text for Eikon: (http://bit.ly/2KqLRZ4) Further company coverage:

01 May 2018

BRIEF-Tonix Pharmaceuticals Receives IND Clearance By U.S. FDA For TNX-102 SL

* TONIX PHARMACEUTICALS RECEIVES IND CLEARANCE BY U.S. FDA FOR TNX-102 SL IN AGITATION IN ALZHEIMER’S DISEASE Source text for Eikon: Further company coverage:

01 May 2018

BRIEF-Tonix Pharmaceuticals To Present FDA Breakthrough Therapy Designated PTSD Program At Microcap Conference

* DESIGNATED PTSD PROGRAM AT THE MICROCAP CONFERENCE IN NEW YORK

04 Apr 2018

BRIEF-Tonix Pharma Ready To File For Approval Of PTSD Treatment In 2019 Based On Study Data

* TONIX PHARMACEUTICALS ACHIEVES 50 PERCENT ENROLLMENT IN PHASE 3 TRIAL OF FDA-DESIGNATED BREAKTHROUGH THERAPY TONMYA® (CYCLOBENZAPRINE HCL SUBLINGUAL TABLETS) FOR THE TREATMENT OF PTSD

03 Apr 2018

BRIEF-Tonix Pharma Reports Q4 Loss Per Share $0.71

* TONIX PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES PROGRAMS UPDATE

12 Mar 2018

BRIEF-Baker Bros Advisors LP Reports 8.9 Pct Passive Stake In Tonix Pharmaceuticals Holding As Of Dec 31, 2017 - SEC Filing

* BAKER BROS ADVISORS LP REPORTS 8.9 PERCENT PASSIVE STAKE IN TONIX PHARMACEUTICALS HOLDING AS OF DEC 31, 2017 - SEC FILING Source text: (http://bit.ly/2HcDj6B) Further company coverage:

13 Feb 2018

BRIEF-Tonix Pharmaceuticals Receives Notice Of Allowance For New U.S. Patent For The Active Ingredient In Tonmya

* TONIX PHARMACEUTICALS RECEIVES NOTICE OF ALLOWANCE FOR NEW U.S. PATENT FOR THE ACTIVE INGREDIENT IN TONMYA (CYCLOBENZAPRINE HCL SUBLINGUAL TABLETS) Source text for Eikon: Further company coverage:

23 Jan 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $125.85 -0.09
Pfizer Inc. (PFE.N) $37.33 -0.03
Novartis AG (NOVN.S) CHF82.20 +1.24
AstraZeneca plc (AZN.L) 5,589.00 -20.00
GlaxoSmithKline plc (GSK.L) 1,549.80 -8.20

Earnings vs. Estimates